uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 831.68 Million USD | 17.98% |
| 2022 | 704.96 Million USD | -12.88% |
| 2021 | 809.18 Million USD | 137.72% |
| 2020 | 340.39 Million USD | -24.13% |
| 2019 | 448.63 Million USD | 63.79% |
| 2018 | 273.9 Million USD | 31.13% |
| 2017 | 208.87 Million USD | 9.78% |
| 2016 | 190.26 Million USD | -28.12% |
| 2015 | 264.69 Million USD | 127.25% |
| 2014 | 116.47 Million USD | 116.45% |
| 2013 | 53.81 Million USD | 630.89% |
| 2012 | 7.36 Million USD | -2.13% |
| 2011 | 7.52 Million USD | -75.09% |
| 2010 | 30.19 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 645.8 Million USD | -11.64% |
| 2024 Q2 | 730.84 Million USD | -5.09% |
| 2024 Q1 | 770.05 Million USD | -7.41% |
| 2023 Q2 | 942.76 Million USD | 49.41% |
| 2023 FY | 831.68 Million USD | 17.98% |
| 2023 Q1 | 631 Million USD | -10.49% |
| 2023 Q4 | 831.68 Million USD | -4.57% |
| 2023 Q3 | 871.55 Million USD | -7.55% |
| 2022 Q1 | 757.15 Million USD | -6.43% |
| 2022 FY | 704.96 Million USD | -12.88% |
| 2022 Q4 | 704.96 Million USD | 10.46% |
| 2022 Q3 | 638.23 Million USD | -8.98% |
| 2022 Q2 | 701.21 Million USD | -7.39% |
| 2021 Q1 | 363.85 Million USD | 6.89% |
| 2021 Q3 | 774.62 Million USD | -1.23% |
| 2021 Q4 | 809.18 Million USD | 4.46% |
| 2021 FY | 809.18 Million USD | 137.72% |
| 2021 Q2 | 784.26 Million USD | 115.54% |
| 2020 Q2 | 385.34 Million USD | -6.98% |
| 2020 FY | 340.39 Million USD | -24.13% |
| 2020 Q1 | 414.24 Million USD | -7.66% |
| 2020 Q4 | 340.39 Million USD | -2.88% |
| 2020 Q3 | 350.5 Million USD | -9.04% |
| 2019 Q4 | 448.63 Million USD | -4.87% |
| 2019 Q3 | 471.59 Million USD | 86.34% |
| 2019 FY | 448.63 Million USD | 63.79% |
| 2019 Q1 | 268.99 Million USD | -1.79% |
| 2019 Q2 | 253.07 Million USD | -5.92% |
| 2018 Q4 | 273.9 Million USD | -2.55% |
| 2018 Q3 | 281.06 Million USD | -8.91% |
| 2018 Q2 | 308.53 Million USD | 60.5% |
| 2018 Q1 | 192.23 Million USD | -8.3% |
| 2018 FY | 273.9 Million USD | 31.13% |
| 2017 FY | 208.87 Million USD | 9.78% |
| 2017 Q3 | 138.98 Million USD | -12.01% |
| 2017 Q1 | 169.63 Million USD | -10.84% |
| 2017 Q4 | 209.64 Million USD | 50.84% |
| 2017 Q2 | 157.96 Million USD | -6.88% |
| 2016 Q3 | 213.98 Million USD | -7.43% |
| 2016 FY | 190.26 Million USD | -28.12% |
| 2016 Q2 | 231.16 Million USD | -8.49% |
| 2016 Q1 | 252.59 Million USD | -4.57% |
| 2016 Q4 | 190.26 Million USD | -11.09% |
| 2015 Q2 | 258.46 Million USD | 164.81% |
| 2015 FY | 264.69 Million USD | 127.25% |
| 2015 Q4 | 264.69 Million USD | -7.62% |
| 2015 Q3 | 286.53 Million USD | 10.86% |
| 2015 Q1 | 97.6 Million USD | -16.2% |
| 2014 Q4 | 116.47 Million USD | -9.41% |
| 2014 Q2 | 138.78 Million USD | -0.08% |
| 2014 Q3 | 128.58 Million USD | -7.35% |
| 2014 Q1 | 138.89 Million USD | 158.12% |
| 2014 FY | 116.47 Million USD | 116.45% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | 45.99 Million USD | 0.0% |
| 2013 Q4 | 53.81 Million USD | -8.69% |
| 2013 Q3 | 58.92 Million USD | 28.12% |
| 2013 FY | 53.81 Million USD | 630.89% |
| 2012 Q4 | 7.36 Million USD | 0.0% |
| 2012 FY | 7.36 Million USD | -2.13% |
| 2011 FY | 7.52 Million USD | -75.09% |
| 2010 FY | 30.19 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -66.62% |
| Dynavax Technologies Corporation | 997.09 Million USD | 16.589% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 40.972% |
| Perrigo Company plc | 10.8 Billion USD | 92.306% |
| Illumina, Inc. | 10.11 Billion USD | 91.774% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.158% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -6.579% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.974% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 96.883% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -273.783% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.486% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1166.082% |
| Waters Corporation | 4.62 Billion USD | 82.025% |
| Biogen Inc. | 26.84 Billion USD | 96.902% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -403.078% |
| Evolus, Inc. | 188.99 Million USD | -340.052% |
| Adicet Bio, Inc. | 207.29 Million USD | -301.21% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -560.889% |
| bluebird bio, Inc. | 619.16 Million USD | -34.325% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -304.133% |
| FibroGen, Inc. | 423.52 Million USD | -96.371% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 92.273% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2841.7% |
| Homology Medicines, Inc. | 47.05 Million USD | -1667.408% |
| Geron Corporation | 394.07 Million USD | -111.048% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 78.284% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -6.917% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 30.617% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -125.702% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 36.072% |
| Zoetis Inc. | 14.28 Billion USD | 94.178% |
| Abeona Therapeutics Inc. | 64 Million USD | -1199.473% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 75.215% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 87.844% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.341% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1386.513% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 72.185% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -402.519% |
| Verastem, Inc. | 149.71 Million USD | -455.504% |
| Nektar Therapeutics | 398.03 Million USD | -108.95% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -41.387% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -321.311% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 74.524% |
| OPKO Health, Inc. | 2.01 Billion USD | 58.657% |
| Exelixis, Inc. | 2.94 Billion USD | 71.734% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 74.421% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -33.816% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -438.708% |
| Imunon, Inc. | 21.91 Million USD | -3694.536% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 20.735% |
| Insmed Incorporated | 1.32 Billion USD | 37.459% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 52.016% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 11.25% |
| TG Therapeutics, Inc. | 329.58 Million USD | -152.343% |
| Incyte Corporation | 6.78 Billion USD | 87.737% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 54.674% |